Webinar
How to get the best out of RAG for scientific research
January 22, 2025 03:30 PM Europe/London
The webinar will be held Weds Jan 22 2025 at 3.30-4.30pm GMT, 10.30-11.30am EST, 7.30-8.30am PST, 4.30-5.30pm CET
Many biopharma organisations are struggling with the challenges of poorly implemented GenAI and RAG, often related to not being able to clearly reference where information has come from and thus not being able to trust the resulting data. How can data quality be better prioritised in RAG implementation?
This panel discussion webinar features RAG experts speaking to the perspectives of both best practices for 'doing RAG' (Jim Webber, Chief Scientist at Neo4j) as well as experts in the field implementing RAG for biopharma research (Krishna Bulusu, AstraZeneca). Daniel Jamieson, CEO at Biorelate, will chair a discussion that dives into the present and future of RAG in scientific research settings. This is a not-to-miss discussion for anyone in data science at biopharma organisations seeking to optimise their RAG strategy and usage.
Jim Webber
Dr. Jim Webber is Neo4j’s Chief Scientist and Visiting Professor at Newcastle University. At Neo4j, Jim leads the Systems Research Group, working on a variety of database systems research topics including query languages and runtimes, scale, and fault-tolerance. He also co-authored several books on graph technology including Graph Databases - 1st and 2nd Editions (O’Reilly), Graph Databases for Dummies (Wiley), and Building Knowledge Graphs (O’Reilly).
Prior to Neo4j, Jim worked on fault-tolerant distributed systems. First at Newcastle University startup Arjuna and then for a variety of clients for global consulting firm ThoughtWorks. Along the way Jim co-authored the distrubuted systems books REST in Practice (O’Reilly) and Developing Enterprise Web Services - An Architect’s Guide (Prentice-Hall).
Krishna Bulusu
Krishna Bulusu is a Director in Oncology Early Data Science at AstraZeneca and leads the Oncology Knowledge Graphs team, bringing together world’s knowledge with internal data to generate novel hypotheses with the fundamental aim of delivering patient benefit. His team’s focus is to accelerate the adoption and value delivered through AI across the drug discovery and development pipeline – from target discovery, patient stratification, to safety risk factors. A key part of his team is also to establish collaborations with leading academic groups, start-ups and industrial partners accelerating democratisation of AI-led discoveries. He previously held a Postdoctoral Research Associate position at the Centre for Molecular Informatics in Cambridge on drug combination predictive modelling in Oncology and rare diseases. Krishna received his PhD from the Institute of Cancer Research in Computational Biology & Chemogenomics, and holds a Master’s degree in Bioinformatics from the University of Edinburgh.
Daniel Jamieson
Dr Daniel Jamieson founded Biorelate after supporting the successful identification of drug repurposing opportunities with Pfizer in a groundbreaking project to curate the first-ever knowledge graph to represent the pain interactome.